Wedbush Maintains Neutral on Nektar Therapeutics, Lowers Price Target to $50
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Wedbush analyst Martin Fan maintains Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and lowers the price target from $80 to $50.
Wedbush analyst Martin Fan maintains Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and lowers the price target from $80 to $50.